We are well positioned to grow
based on our existing global footprint
North America
- • 10 Active SITEs
- • 4 setups ongoing
- • 245K NeuraCeq dose capacity
FDA approves disease-modifying drug
Expanding manufacturing partnerships
Potential investment in new sites
Europe
- • 16 Active SITEs
- • 5 setups ongoing
- • 250K NeuraCeq dose capacity
EMA approval to follow FDA by 6-9m
Rest of World
- • 7 Active SITEs
- • 7 setups ongoing
- • 170K NeuraCeq dose capacity
Upcoming NeuraCeq approval in China
Upcoming NeuraCeq approval in Brazil